Medical College of Wisconsin
CTSICores SearchResearch InformaticsREDCap

Exceptional Response to Everolimus in a Patient with Metastatic Castrate-Resistant Prostate Cancer Harboring a PTEN Inactivating Mutation. Case Rep Oncol 2020 Jan-Apr;13(1):456-461

Date

05/14/2020

Pubmed ID

32399016

Pubmed Central ID

PMC7204854

DOI

10.1159/000506625

Scopus ID

2-s2.0-85084410749

Abstract

Prostate cancer is among the most common types of cancer in men. Early detection and proper medical intervention is crucial to ensuring successful treatment. Here we describe a patient clinically presenting with castrate-resistant prostate carcinoma. Comprehensive genomic profiling identified a PTEN inactivating mutation in the patient's tumor. After being heavily pretreated, the patient showed stable disease on everolimus, a PI3K-Akt-mTOR pathway inhibitor.

Author List

Kmak JA, Agarwal N, He Y, Heilmann AM, Miller VA, Ross JS, Pal SK, Ali SM, Kilari D

Author

Deepak Kilari MD Associate Professor in the Medicine department at Medical College of Wisconsin